Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
This grant supports research into the neurobiological and behavioral causes of mood and psychosis disorders that emerge or worsen during menopause.
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | January 7, 2028 (Closing)
Funding Amounts: No budget cap; requests must reflect project needs; up to 5 years; no cost sharing required
Summary: Supports mechanistic and translational research on mood disruption and psychosis during the menopausal transition to identify future intervention targets.
Key Information: Studies must validate menopausal-transition status and investigate mechanisms at multiple levels of analysis; nonhuman animal studies are excluded.
Description
This NIH R01 program, administered by the National Institute of Mental Health (NIMH), supports research on the onset and worsening of mood disruption, emotion dysregulation, and psychosis during the menopausal transition. The Office of Research on Women’s Health may co-fund applications. The goal is to clarify neurobiological, behavioral, and social mechanisms and identify targets for future mental health treatment or prevention.
Research may examine reproductive steroids, brain circuits, biological and psychosocial risk factors, or mechanisms linking symptoms to increased mortality. Dimensional approaches spanning symptom severity are encouraged, although existing diagnostic categories may also be used. The program welcomes interdisciplinary teams, including researchers with lived experience of perimenopausal depression or psychosis. Mechanistic clinical trials are supported, but studies evaluating intervention safety, efficacy, effectiveness, management, or implementation are not.
